Article Text

Download PDFPDF
Selective reduction of amyloid β42 discriminates Alzheimer’s disease from Huntington’s disease: indication for distinct pathological events in amyloid β peptide aggregation
  1. B Mollenhauer1,
  2. M Bibl2,
  3. H Esselmann2,
  4. P Steinacker3,
  5. C Trenkwalder4,
  6. P Brechlin5,
  7. J Wiltfang6,
  8. M Otto7
  1. 1Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
  2. 2Department of Psychiatry, University of Goettingen, Goettingen
  3. 3Department of Neurology, University of Ulm, Ulm, Germany
  4. 4Paracelsus-Elena-Klinik, University of Goettingen, Kassel, Germany
  5. 5Department of Neurology, University of Goettingen
  6. 6Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany
  7. 7Department of Neurology, University of Ulm, Germany
  1. Correspondence to:
 Dr Brit Mollenhauer
 Department of Neurology, Center for Neurologic Diseases, Brigham and Women’s Hospital, 77, Avenue Louis Pasteur, HIM 764, Boston, MA 02115, USA; bmollenhauer{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Huntington’s disease and Alzheimer’s disease are neurodegenerative disorders associated with the aggregation of misfolded polypeptides, leading to amyloids and neuronal damage.1

Huntington’s disease is caused by expanded glutamine repeats that encode polyglutamine tracts of the gene encoding the huntingtin protein, and is associated with dementia. Polyglutamine tracts in Huntington’s disease form amyloid structures in the cerebral cortex and in the striatum.2

In Alzheimer’s disease, extracellular amyloid β (Aβ) peptides form amyloid plaques in the brain, and lower levels of Aβ1–42 in the cerebrospinal fluid (CSF) may reflect neuropathological processes in amyloid-related disorders. A quantitative urea-based Aβ-sodium dodecylsulphate–polyacrylamide gel electrophoresis with western immunoblot (Aβ-SDS–PAGE/immunoblot) recently showed the regular abundance of Ct-truncated Aβ peptides in the CSF and displayed disease-specific variations.3,4

The morphological substrate of dementia in Huntington’s disease is controversial, and concomitant Alzheimer’s disease pathology has been discussed.5 Thus, Alzheimer’s disease and Huntington’s disease share pathological similarities and may even culminate in a common mechanism of pathogenesis or concomitance in which these protein aggregates affect cellular functions and cause neuronal death.


Of the 69 patients in the study, 16 had Huntington’s disease, 16 had Alzheimer’s disease, 20 had other choreatic diseases and 17 were neurological controls without dementia. Mean age did not differ significantly between diagnostic groups, except between those with Alzheimer’s disease and those with Huntington’s disease (p = 0.002). The Mini-Mental Status Examination (MMSE) score was significantly different between the group with other choreatic diseases and that with Alzheimer’s disease (p = 0.002).

Clinical diagnosis in patients with Huntington’s disease (6 men and 10 women) was confirmed by DNA analysis. Their median age …

View Full Text


  • BM and MB contributed equally to this work.

  • Published Online First 20 March 2006

  • Funding: This study was supported in part by a grant from the Bundesministerium für Gesundheit (MO) and by the Bundesministerium für Forschung und Technik (MO, JW).

  • Competing interests: None declared.